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Atherosclerotic lesions of the thoracic aorta have recently been recognized as an important
cause of stroke and peripheral embolization, which may result in severe neurologic damage as
well as multiorgan failure and death. Their prevalence is ;27% in patients with previous
embolic events. Transesophageal echocardiography is the modality of choice for the diagnosis
of these atheromas, although computed tomography, magnetic resonance imaging and
intraoperative epiaortic ultrasound are complementary. Two clinical syndromes account for
the embolic phenomena, atheroemboli and, more commonly, thromboemboli. In addition to
such superimposed thrombi, plaque thickness (especially $4 mm) also correlates with embolic
risk. This risk is high, with 12% of patients having a recurrent stroke within approximately
one year, and up to 33% of patients having a stroke or peripheral embolus. In addition, aortic
atheromas (as seen with intraoperative transesophageal echocardiography and intraoperative
epiaortic ultrasound) are an important cause of stroke during heart surgery requiring
cardiopulmonary bypass. Such strokes occur during ;12% of cardiac operations employing
cardiopulmonary bypass when aortic arch atheromas are seen with transesophageal echocar-
diography (six times the general intraoperative stroke rate). Although anticoagulant strategies
have been reported with encouraging results in nonrandomized studies, prospective, random-
ized data must be developed before an effective and safe treatment strategy can be determined.
This review details the current state of knowledge in this area, including the clinical and
pathologic evidence that thoracic aortic atherosclerosis is an important embolic source, data
which guide current therapy and future directions for clinical investigation. (J Am Coll
Cardiol 2000;35:545–54) © 2000 by the American College of Cardiology
Stroke and peripheral embolization are major causes of
morbidity and mortality, and stroke is the third leading
cause of death in the U.S. (1). The established risk factors
for stroke include increasing age, male gender, heredity,
previous stroke, hypertension, smoking, diabetes, carotid
artery disease, heart disease and polycythemia. There are
also many secondary risk factors, such as climate (excessive
heat or cold), socioeconomic status and geographic area (2).
As recently as the 1950s, 55% of strokes were thought to
be caused by cerebral vasospasm (3). This changed when
Harvard neurologist C. Miller Fisher stressed the etiologic
role of emboli from carotid artery atherosclerotic plaques
(4). Until the 1990s, carotid disease and atrial fibrillation
were the two entities that dominated the clinical approach
to patients with stroke and peripheral embolization. Despite
the recognition of these two important sources of emboli,
stroke data banks as late as 1989 still indicated that in up to
40% of patients, no etiology can be found (5,6). Thus,
“cryptogenic stroke” has continued to be a diagnostic di-
lemma.
Transthoracic echocardiography has been ordered fre-
quently but is frustratingly negative in looking for sources of
emboli. Transesophageal echocardiography is a safe, mini-
mally invasive procedure with a very low risk of complica-
tions (7). In 1990, a new finding was reported in three
patients with embolic disease (8). In these patients, trans-
esophageal echocardiography revealed protruding athero-
sclerotic plaques in the aortic arch. These initial patients
were followed by many case-control (9–11) and then
prospective (12–14) studies documenting the association
between aortic atheromas and embolic phenomena. More-
over, the mobile components seen attached to these athe-
romas on transesophageal echocardiography have proven to
be thrombi (15–17)—the source of the devastating embolic
complications that occur in 20% to 33% of these patients in
just one year (12).
This review details the current state of knowledge about
thoracic aortic atherosclerosis, including the clinical and
pathologic evidence that it is an important embolic source,
data which guide current therapy and future directions for
clinical investigation.
PREVALENCE OF AORTIC ATHEROMAS IN PATIENTS
WITH EMBOLI: CASE-CONTROL STUDIES
After several case series (8,18–20) which found aortic
atheromas in patients with emboli, retrospective case-
control studies documented a significant association be-
tween stroke and peripheral emboli and the presence of
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thoracic aortic atheromas seen on transesophageal echocar-
diography (9–11,21), on autopsy (22,23) and with intraop-
erative epiaortic ultrasound during cardiac surgery (24). The
prevalence of atheromas in the aortic arch in patients with
embolic disease, found by three different groups of investi-
gators, was remarkably consistent—27% (9), 21% (11) and
26% (21). In contrast, significant atheromas were found in
only 9%, 4% and 13% of control subjects, respectively.
Multivariate analyses showed a highly significant odds ratio
for the prevalence of previous stroke in patients with
atheromas—3.2, 8.2 and 3.6, respectively.
Perhaps most importantly, the prevalence of aortic athe-
romas seen in these studies of stroke patients (21% to 27%)
is about the same magnitude as the prevalence of carotid
disease (10% to 13%) and atrial fibrillation (18% to 30%)
reported in two recent large series of consecutive stroke
patients (10,11).
Thus, these case-control data documented a significant
association between aortic plaque and embolic disease, but
because all of these studies were retrospective, a causal
relation was not yet established. Intriguing information
from an early case-control study did suggest causality. Most
of the arch atheromas were located distal to the innominate
artery, and only 18% of embolic events had occurred in the
right brain (vs. the left brain or periphery) (9). Obviously,
arch atheromas distal to the innominate artery cannot
embolize in a retrograde fashion to the right brain and may
embolize to the left carotid system or the periphery.
AORTIC ATHEROMAS AND CAROTID ARTERY DISEASE
The association between atheromas and embolic disease in
the studies discussed earlier was independent of other risk
factors for stroke, most prominently carotid disease and
atrial fibrillation (patients with these findings were excluded
from the first study [9], and multivariate analysis controlled
for them in the other two studies [11,12]). Although aortic
atheromas are therefore independent risk factors for stroke
and peripheral emboli, it is not surprising that patients with
significant carotid atherosclerosis also have a higher preva-
lence of aortic arch atherosclerosis than those without
carotid disease, and therefore they have more than one
potential source of embolization. In one retrospective study,
aortic arch atheromas were found in significantly more who
had a stroke/transient ischemic attack (TIA) patients with
carotid stenosis (38% vs. 17% of patients who had a
stroke/TIA without carotid stenosis) (25). That study also
found that mobile thrombi superimposed on the aortic arch
atheromas were exclusively found in patients whose carotid
stenosis exceeded 80%. Thus, the patients with the highest
risk carotid lesions also had the highest risk aortic plaques.
Therefore, when presented with a patient with stroke and
significant carotid stenosis, it is important to also consider
the possibility that the embolic event may have originated in
the aorta. When the neurologic event is contralateral to the
carotid stenosis or is associated with peripheral (e.g., renal,
lower extremity) emboli, the aorta should be evaluated with
transesophageal echocardiography. This is also true in
patients who have neurologic events after recovery from a
technically successful carotid endarterectomy.
AORTIC ATHEROMAS AND ATRIAL FIBRILLATION
The Stroke Prevention in Atrial Fibrillation (SPAF) inves-
tigators have reported a series of 382 patients with “high
risk” nonvalvular atrial fibrillation (age .75 years, hyper-
tension, previous stroke) who had transesophageal echocar-
diography (26). Of these, 134 (35%) had complex aortic
plaque (mobile, ulcerated, size $4 mm) on transesophageal
echocardiography. These patients with plaque had a stroke
risk in one year of 12% to 20%. The risk was dramatically
lower, only 1.2%, in the patients with high risk nonvalvular
atrial fibrillation who did not have significant aortic plaque,
regardless of therapy with warfarin or aspirin. Therefore, if
a stroke occurs in the setting of high risk nonvalvular atrial
fibrillation, and when an “upstream” aortic atheroma is
present, the atrial fibrillation may not be the cause of the
embolic event.
PLAQUE SIZE AND EMBOLIC RISK
The earliest case series and case-control studies in the U.S.
used a cutoff of $5 mm thickness to classify significant
aortic atheromas (8,9,19). However, the French Aortic
Plaque in Stroke (FAPS) group evaluated a large number of
patients with varying plaque thicknesses and found not only
that increasing plaque thickness imparted increasing risk,
but also that with a plaque thickness of $4 mm the odds
ratio was significantly greater (10). The odds ratio for
plaques ,1 mm was 1.0 (no increased risk); for 1 to 3.9 mm
plaques it was 3.9; and for plaques $4 mm it was much
higher, 13.8. This study also supports causality with respect
to arch atheromas and stroke, instead of these plaques being
just a marker for stroke risk, as the odds ratio for stroke in
patients with plaque in the descending aorta (which could
not embolize to the head) was only 1.5 for the largest
plaques, $4 mm (vs. an odds ratio of 13.8 for those in the
arch, upstream from the cerebral circulation).
Abbreviations and Acronyms
CAD 5 coronary artery disease
CT 5 computed tomography
HMG-CoA 5 hydroxymethyl glutaryl coenzyme A
INR 5 international normalized ratio
LDL 5 low density lipoprotein
MIDCAB 5 minimally invasive direct coronary
artery bypass graft surgery
MRI 5 magnetic resonance imaging
MRA 5 magnetic resonance angiography
TIA 5 transient ischemic attack
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PLAQUE MORPHOLOGY AND EMBOLIC RISK
From the earliest studies, the presence of mobile lesions
(thrombi) superimposed on aortic atheromas has been
recognized to impart a high embolic risk, which will be
discussed subsequently. Other characteristics of the lesions
seen on transesophageal echocardiography have been eval-
uated as well. In one study, the presence of ulceration
$2 mm in aortic plaques seen on transesophageal echocar-
diography was found to correlate with cryptogenic stroke;
ulcerations were present in 9 (39%) of 23 patients with
cryptogenic stroke, but were seen in only 2 (8%) of 26
patients with stroke of known cause and 4 (7%) of 57
patients without stroke (27).
One large group of 334 patients .60 years old with
stroke was evaluated with transesophageal echocardiography
and was followed for two to four years (28). These authors
found that hypoechoic plaques, calcification and ulceration
were more common in plaques $4 mm in thickness. In that
study, the presence of ulceration did not increase the relative
risk of vascular events in patients with plaques $4 mm (the
relative risk was 4.3 in those with ulceration and 5.7 in those
without ulceration). However, the absence of calcification
did increase the risk in patients with plaques $4 mm. The
highest risk was found in patients with noncalcified plaques
$4 mm, in whom the relative risk was 10.3. The lack of
calcification was associated with a higher risk, regardless of
the other morphologic features of the plaque.
It is possible that these noncalcified plaques may be the
ones that are lipid-laden and therefore “vulnerable.” This
theory is supported by a pathologic study that evaluated the
size of the lipid pool and the number of smooth muscle cells
and macrophages in human aortic plaques that were intact
as compared with those that had superimposed thrombi
(29). These authors found that the presence of superim-
posed thrombi is characteristic of plaques with a high
proportion of their volume occupied by extracellular lipid
and in which there was a shift toward a preponderance of
monocytes/macrophages as compared with smooth muscle
cells in the cap.
PATHOLOGIC CORRELATES AND SUPERIMPOSED
THROMBI
In 1992, an important autopsy study examined 500 patients
with stroke and other neurologic diseases (22). The major
finding was that ulcerated plaques were present in the aortic
arch in 62 (26%) of 239 patients with cerebrovascular
disease, but in only 13 (5%) of the 261 patients with other
neurologic diseases (p , 0.001). Furthermore, the preva-
lence of ulcerated plaques in the aortic arch was much
higher (61%) in 28 patients with “cryptogenic stroke,” as
compared with 22% in those with stroke and carotid disease
or another known cause of stroke. These authors did not
identify thrombi on the aortic lesions; however, thrombi
may have been lost due to washing and preparation of the
specimens or lysis before pathologic examination.
Since the earliest reports, investigators have found that a
significant proportion (25% to 50%) of protruding athero-
mas seen on transesophageal echocardiography have a mo-
bile component that moves freely with the blood flow.
These may range in size from 1 mm to several centimeters.
Early case reports of two such patients who underwent heart
surgery documented that these mobile lesions were in fact
thrombi superimposed on atherosclerotic plaque (15,30).
The following year, thrombi were also documented in an
another three patients with mobile lesions on transesopha-
geal echocardiography (31), and mobile lesions have been
reported to disappear after heparin or warfarin therapy
(32,33) or thrombolysis (34).
The presence of thrombi on aortic plaques was further
documented in a recent autopsy series (35). This study
reported aortic thrombi in 17 of 120 consecutive autopsies,
as well as a significant association between complex plaque
(thrombus, ulceration or debris) and previous emboli. In
addition, pathologic examination of mobile lesions in the
aorta seen on transesophageal echocardiography was re-
cently reported in six patients with aortic aneurysm or
dissection, and thrombi were found at the time of surgery
(17).
In a study using repeat transesophageal echocardiography
over a period in the same patients with aortic atheromas,
changes in lesion morphology were noted (36). On the
second transesophageal echocardiographic examination,
there were new mobile lesions present on plaques where
there had been none initially in 11 (61%) of 18 patients.
Furthermore, 7 of 10 mobile lesions present on the first
examination had resolved (or embolized?) by the time of the
second examination. It is not surprising that these plaques in
the aorta may be unstable, and that superimposed throm-
bosis may occur and recur in the same way that it does in the
coronary circulation. This has important therapeutic impli-
cations, which will be discussed subsequently.
EMBOLIC SYNDROMES IN PATIENTS WITH AORTIC
ATHEROMAS: THROMBUS EMBOLIZATION VERSUS
ATHEROEMBOLI (CHOLESTEROL CRYSTAL EMBOLI)
It is common for thrombi to form on aortic atheromas, and
embolization to the femoral arteries has been found at
surgery to be due to thrombus (15,30). A different clinical
picture—the atheroemboli syndrome—is also associated
with aortic disease. This consists of renal failure, skin
lesions, blue toes and multiorgan findings caused by cho-
lesterol emboli (37). It may develop spontaneously or may
result from arterial manipulation during cardiac catheteriza-
tion, intra-aortic balloon pumping or the institution of
cardiopulmonary bypass. The atheroemboli may occlude
small arteries and they can be seen as refractile bodies in the
retinal arteries. They can also be diagnosed microscopically
with biopsy of the skin, muscle or kidney. Recent reports
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have shown protruding aortic atheromas on transesophageal
echocardiography in patients with atheroemboli in the skin,
muscle and kidneys (38,39). However, the syndrome of blue
toes and renal failure has not often been observed in patients
with aortic atheromas on transesophageal echocardiography
and was reported in only one patient treated with warfarin
in the SPAF III study of patients with aortic atheromas
(26). More subtle findings may occur, as was reported in a
study of patients undergoing cardiac surgery. Increasing
levels of creatinine were noted to be associated with increas-
ing severity of aortic atherosclerosis (40).
Because the mobile lesions seen on transesophageal echo-
cardiography are thrombi, it is likely that the large majority
of medium to large artery occlusions (cerebral, femoral,
renal) that occur in patients with aortic atheromas are due to
the embolization of thrombus.
AORTIC ATHEROMAS AND RISK FACTORS FOR
ATHEROSCLEROSIS
Not surprisingly, the presence of aortic atheromas is related
to the traditional risk factors for atherosclerosis. Atheromas
are most often seen in the elderly (the average age of those
with aortic atheromas is ;70 years [12]), although athero-
mas have been seen in patients as young as 43 years (15).
Hypertension and hypercholesterolemia are also signifi-
cantly more common in patients with aortic atheromas (41),
and a positive correlation between aortic atherosclerosis and
smoking has also been documented (42).
In addition to these “traditional” risk factors, both fibrin-
ogen levels (43) and homocysteine levels (44) have been
positively correlated with aortic atherosclerosis. In the latter
study, which measured plaque in three locations in the
thoracic aorta on transesophageal echocardiography, a sig-
nificant correlation between total plaque burden and homo-
cysteine levels was seen, as well as an inverse relation
between plaque burden and pyridoxal-59-phosphate (vita-
min B6) levels.
AORTIC ATHEROMAS AS A MARKER FOR CORONARY
ARTERY DISEASE (CAD)
Radiographic studies have reported an association between
aortic plaque seen on chest X-ray and the subsequent
development of clinical CAD (45). Aortic plaque seen on
transesophageal echocardiography has been correlated with
a higher prevalence of CAD (33) and the presence of
significant angiographic coronary artery stenosis (46). In
addition, the lack of aortic plaque on transesophageal
echocardiography has also been shown to be predictive of
the absence of CAD (47).
Transesophageal echocardiography was performed on 61
patients who had previously undergone coronary angiogra-
phy for the evaluation of CAD or valvular heart disease or
for miscellaneous indications (46). The sensitivity and
specificity of the presence of aortic plaque for the prediction
of significant coronary stenosis were both 90%. The positive
predictive value of plaque detected by transesophageal
echocardiography was 95%, and the negative predictive
value was 82%. The authors concluded that the detection of
aortic plaque by transesophageal echocardiography appears
to be a marker for the presence of obstructive coronary
artery disease. In 1997, another group also found that the
presence of aortic plaque on transesophageal echocardiog-
raphy correlated with angiographic coronary stenosis, but
only among 60 patients ,70 years old (48). Among 24
patients .70 years old, aortic plaque found on transesoph-
ageal echocardiography failed to be a significant predictor of
coronary disease (plaque was seen in 12 of 13 older patients
with coronary disease, but also in 9 of 10 older patients
without coronary obstruction). Further investigation in
larger groups of patients is necessary.
OTHER IMAGING MODALITIES
Although transesophageal echocardiography was the first
procedure to gain acceptance for imaging of thoracic aortic
atheromas, other imaging modalities have a role. Dual
helical computed tomographic (CT) scanning was used to
evaluate 32 patients who also had transesophageal echocar-
diography (49). The sensitivity and specificity of the CT
study for the detection of protruding aortic atheromas seen
on transesophageal echocardiography were 87% and 82%,
respectively. Magnetic resonance imaging (MRI) has also
been used to detect thrombus in the aortic arch (50,51) and
to differentiate aortic thrombus from intravascular tumor
(pulmonary artery metastatic melanoma) (52). Rapid acqui-
sition techniques employed in the last study (52) may help
to overcome flow artifacts which may obscure intra-arterial
masses on contrast-enhanced electrocardiographic-gated
MRI studies. Because of the potential of MRI to detect
aortic atheromas, a study was done to compare breath-hold,
gadolinium-enhanced three-dimensional magnetic reso-
nance angiography (MRA) with transesophageal echocar-
diography (53). This study showed that although trans-
esophageal echocardiography and MRA were comparable
for detecting atheromas in the ascending aorta and descend-
ing aorta, plaque thickness was significantly larger in the
aortic arch on transesophageal echocardiography as com-
pared with MRA. Fewer “high risk” plaques $5 mm were
detected by MRA. Both CT and MRI studies have the
potential to visualize plaques in the small area masked by the
tracheal air column on transesophageal echocardiography,
and the three modalities appear to be complementary.
Intraoperative epiaortic ultrasound has been used in the
operating room to visualize atheromas in the ascending
aorta (24,54). For patients undergoing cardiac surgery, two
studies have reported that this technique is more sensitive
than transesophageal echocardiography for finding disease
in the ascending aorta (55,56). Transthoracic echocardiog-
raphy has also been used to visualize plaque in the ascending
aorta and aortic arch. In one initial study, 20 patients were
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evaluated with both transthoracic and transesophageal tech-
niques (57). However, the resolution of images obtained by
the transthoracic approach is currently not as high as that of
those images obtained with a transducer in the esophagus.
At this time, transesophageal echocardiography is the pro-
cedure of choice for the detection, measurement and char-
acterization of thoracic aortic atheromas in both inpatients
and outpatients. For patients undergoing cardiac surgery,
intraoperative epiaortic ultrasound has been found to be
superior for evaluating the ascending aorta, and this tech-
nique can be used to complement the information on the
aortic arch that is obtained by intraoperative transesopha-
geal echocardiography.
PROSPECTIVE STUDIES AND THE INCIDENCE OF
FUTURE EVENTS
The case series and case-control studies discussed earlier
document a significant association between aortic atheromas
and embolic disease, but do not establish a causal relation.
More recently, there have been several prospective studies
that have looked at the risk of future embolic stroke and
peripheral emboli in patients with protruding atheromas in
the thoracic aorta seen on transesophageal echocardiogra-
phy (12–14) and intraoperative epiaortic ultrasound in the
operating room during heart surgery (58). The studies using
transesophageal echocardiography found both an incidence
of stroke averaging 12% in just one year and an incidence of
all embolic events (stroke and peripheral) of up to 33% in
the same short period. The odds ratios for the risk of future
events (4.3, 3.5 and 4.3) were consistent in the transesoph-
ageal echocardiographic studies and lower (1.3) in the large
series of patients with ascending aortic atherosclerosis on
intraoperative epiaortic ultrasound. This may reflect the fact
that fewer plaques are seen in the ascending aorta than in
the arch or descending aorta. The study using intraoperative
epiaortic ultrasound also documented a higher incidence of
mortality; the odds ratio was 1.38 for death during the
follow-up period of up to seven years. The death rate was
15.4% for patients with a normal ascending aorta and much
higher, 43.4%, in those with severe ascending atherosclero-
sis (.5 mm, or ulcerated or mobile lesions).
It is important to remember that although the brain is the
most common site of embolization, many patients have
severe morbidity and mortality secondary to peripheral
embolization from these lesions. Patients with atheromas
may have severe ischemia or infarction of the legs, kidneys
or bowel, and in some patients, all of these vascular beds are
affected, resulting in multiorgan failure and death (12).
EMBOLIC EVENTS DURING AORTIC MANIPULATION
Left heart catheterization and intra-aortic balloon
pumping. Cardiac catheterization or placement of an
intra-aortic balloon pump may cause embolization from
aortic atheromas (59,60). One group found that in 7 (15%)
of 48 patients with protruding atheromas on transesopha-
geal echocardiography, an embolic event occurred as a result
of cardiac catheterization through the femoral artery (59).
They also found such events in four of seven patients with
significant aortic atheromas who had balloon pump place-
ment. The highest risk patients were those with mobile
thrombi. Embolic events occurred in 9 (43%) of 21 of these
patients, but in only 2 (7%) of 27 patients with atheromas
but no mobile thrombi on transesophageal echocardiogra-
phy. It should be noted that these numbers do not reflect
the incidence of embolic complications during cardiac
catheterization, which is actually low (0.5% of strokes in one
large series) (61). However, when embolic complications do
occur, aortic atheromas are a common association.
In a prospective evaluation of 1,000 consecutive patients
undergoing coronary interventions, the amount of visible
atheromatous material retrieved from guiding catheters that
had been passed up the aorta from the femoral artery was
recorded (62). The authors found that in .50% of cases,
guiding catheter placement is associated with scraping of
debris from the aorta, and they recommended allowing the
debris to exit the back of the catheter to prevent the
injection of atheromatous material into the vascular tree.
Cardiac surgery. Embolic stroke and peripheral emboli
may complicate cardiac surgery involving cardiopulmonary
bypass, especially in the elderly. These events occur in 2% to
7% of patients in reported series (63–65). Various theories
have been advanced to explain these embolic complications,
including air emboli and manipulation of the aorta during
proximal graft anastomosis, cross-clamping, palpation and
“sandblasting” from the cannula flow. In one series, patients
with aortic arch atheromas had a significantly higher inci-
dence of intraoperative stroke (3 [15%] of 23) than did those
without atheromas (2 [2%] of 107) (66). One of the patients
in this study had an intraoperative stroke after the cannula
was observed going through an aortic arch plaque with a
mobile thrombus. The thrombus was no longer seen after
cannulation.
This study (66) also found that palpation of the aorta by
the surgeon did not identify the atherosclerotic disease seen
on transesophageal echocardiography in 83% of those with
significant plaque. Underestimation of atherosclerotic dis-
ease of the ascending aorta by palpation had been docu-
mented previously in a study of intraoperative epiaortic
ultrasound (67) and was confirmed in a subsequent report in
which palpation identified only 38% of significant ascending
aortic plaques and underestimated their severity (68).
More recently, 268 patients with aortic arch atheromas
$5 mm on transesophageal echocardiography were evalu-
ated after cardiac surgery (69). Arch atheromas proved to be
a highly significant risk factor for intraoperative stroke,
which occurred in 11.6% (the general intraoperative stroke
risk at that institution is 2.2%). In addition, this study (69)
evaluated a subgroup of 43 patients (retrospectively) in
whom aortic arch endarterectomy was done in an effort to
prevent intraoperative stroke. The stroke risk was nearly
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three times higher (34.9%) if an endarterectomy was done
just before coronary bypass or valve surgery. Furthermore,
the strokes that occur in patients with arch atheromas are
major neurologic events. The in-hospital mortality rate in
those patients with intraoperative stroke was 39%, and many
of the survivors were severely disabled. The patients with
intraoperative stroke had a significantly (nearly four times)
greater number of days intubated and a significantly (ap-
proximately three times) higher incidence of prolonged
awakening from anesthesia. As a result, their recovery room
and length of stay in the intensive care unit were signifi-
cantly longer. The total hospital length of stay was also very
long for patients with arch atheromas (six weeks), both with
and without stroke (comorbidity other than stroke was high
in these patients with atheroma as well). Finally, the
in-hospital mortality rate for the group of 268 patients with
aortic arch atheromas on transesophageal echocardiography
was 14.9%, more than double the general rate. Clearly,
patients with aortic arch atheromas represent a high risk
group for cardiac surgery, and this must be factored into the
risk–benefit analysis that is done for these patients when
cardiac surgery requiring cardiopulmonary bypass is con-
templated.
MANAGEMENT OF PATIENTS WITH AORTIC
ATHEROMAS
The proper management of patients with protruding aortic
atheromas is not yet known. This section summarizes the
current data that may be used to design a therapeutic
approach to these patients.
Hydroxymethyl glutaryl coenzyme A (HMG-CoA) re-
ductase inhibitors. These reductase inhibitors, which
block cholesterol synthesis and result in an increase in low
density lipoprotein (LDL) receptor synthesis (and a drop in
serum LDL), have become widely used in the primary and
secondary prevention of coronary artery disease. A recent
meta-analysis of randomized trials of these drugs in the
prevention of myocardial infarction looked at the incidence
of stroke (not the primary end point of the trials) (70). Data
from a total of 49,477 patients treated with “statins” in 28
trials were pooled and compared with data from 56,636
control subjects. The relative risk of fatal and nonfatal stroke
in treated patients was 0.76 (95% confidence interval 0.62 to
0.92). The authors concluded that in hyperlipidemic pa-
tients who have not previously had a stroke, HMG-CoA
reductase inhibitors reduce the incidence of stroke. Stroke
was a prespecified secondary end point in the Cholesterol
And Recurrent Events (CARE) trial (71). Pravastatin
versus placebo was used in 4,159 subjects with “average”
cholesterol and LDL levels (mean 209 vs. 139 mg/dl) who
had a myocardial infarction an average of 10 months before
the study. Those treated with pravastatin had a 32%
reduction in all-cause stroke and a 27% reduction in stroke
or TIA. In addition, there was no increase in hemorrhagic
stroke with pravastatin.
In a study of eight patients with familial hypercholester-
olemia, plaque area was evaluated using transesophageal
echocardiography (72). With LDL-apheresis (n 5 5), there
was a reduction in plaque area, although with standard
therapy in three patients no reduction was seen.
It does seems reasonable to consider the use of HMG-
CoA reductase inhibitors in patients with aortic atheroscle-
rosis. As noted earlier, aortic plaques that undergo throm-
bosis have been found to contain more lipid (29), and lipid
reduction is one mechanism by which statins may stabilize
plaques and prevent stroke. Statins have also been found to
reduce thrombin generation by platelets, which is elevated
in hypercholesterolemic patients (73). This could play a role
in reducing plaque thrombosis. Actual regression of plaque
size in the aorta could be another mechanism, as shown in
one recent study in which patients with familial heterozy-
gous hypercholesterolemia and aortic atheromas on trans-
esophageal echocardiography were treated with pravastatin
(74). These authors found that the atheroma grade re-
mained stable on treatment in seven patients, progressed in
three and regressed in six. Those with regression had a
significantly greater reduction in plasma LDL.
Antithrombotic and anticoagulant treatment. Because
thrombi have been documented to develop on and embolize
from aortic atheromas, it may be logical to assume that
anticoagulant treatment with warfarin may be beneficial in
these patients. In fact, these mobile lesions have been noted
to disappear during anticoagulant therapy (32,75) or with
the use of a thrombolytic agent (34). However, there is
significant resistance to the use of warfarin in patients with
aortic atherosclerosis because of the theoretic risk of plaque
hemorrhage aggravating the atheroemboli syndrome (“blue
toes,” often with renal failure or intestinal infarction [76]).
There have been reports of individual patients with this
syndrome worsening during anticoagulation (77,78), as well
as a report of improvement, with resolution of an aortic
thrombus on anticoagulation in a patient with the athero-
emboli syndrome (16). Cholesterol emboli have been doc-
umented on skin, muscle and renal biopsy in patients with
aortic atheromas seen on transesophageal echocardiography
(39,40). However, the risk of clinically apparent atheroem-
boli syndrome during warfarin therapy in patients with
aortic atheromas on transesophageal echocardiography ap-
pears to be low (only one episode in 134 patients in the
SPAF trial) (79).
Three reports shed light on the question of whether or
not warfarin will prove to be beneficial in patients with
aortic atheromas. The first described 31 patients with
mobile lesions in the aorta on transesophageal echocardiog-
raphy (80). There was a higher incidence of vascular events
in patients who were not treated with warfarin as compared
with those given warfarin (at the discretion of the referring
physicians) (45% vs. 5%). Strokes occurred in 3 of 11
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patients not treated with warfarin, and in none of those
treated with warfarin.
The second report is from the Stroke Prevention in Atrial
Fibrillation Investigators Committee on Echocardiography
(26). This was a randomized trial of patients with “high
risk” nonvalvular atrial fibrillation. Because transesophageal
echocardiography was done, the results for patients with
both atrial fibrillation and aortic plaque could be reported.
The risk of stroke in one year in 134 patients with complex
aortic plaque was found to be reduced from 15.8% (11
events) in those treated with fixed low dose warfarin plus
aspirin (International Normalized Ratio [INR] 1.2 to 1.5)
to only 4% (3 events) in those treated with adjusted-dose
warfarin (INR 2 to 3). Therefore, there was a 75% risk
reduction for patients with atheromas who received “thera-
peutic range” anticoagulation. Although these patients with
atrial fibrillation were randomized to the two treatment
arms without regard for the presence or absence of aortic
plaque, there were fewer strokes in patients with atheromas
who were treated with full anticoagulation. As noted earlier,
there was only one episode of the atheroemboli syndrome in
warfarin-treated patients.
The third report was an observational study of 129
patients who were found to have aortic atheromas on
transesophageal echocardiography, which was done to look
for a source of cerebral or peripheral embolization (81)
(27.5%) prevalence of atheroma, the same as in previous
studies [9]). Treatment with oral anticoagulation, aspirin or
ticlopidine was not randomly assigned. There was a signif-
icant reduction in the number of embolic events in patients
with plaques $4 mm who received oral anticoagulants (0
events in 27 patients vs. 5 events in 23 patients treated with
antiplatelet agents). For patients with mobile lesions, there
was a significant reduction in mortality while they were on
anticoagulants, although the trend toward fewer embolic
events did not reach statistical significance in this group.
The data from these three reports suggest that warfarin is
not harmful in patients with aortic atheromas, and in fact,
there were fewer strokes in the patients who were given
warfarin by their physicians. However, it is important to
note that these studies are not randomized trials of treat-
ment for patients with atheromas, and the numbers are
relatively small. Clearly, a trial with sufficient power to
detect a significant treatment effect (or harm) should be
done to evaluate the possible efficacy of anticoagulation
(warfarin) and various antithrombotic therapies in patients
with significant thoracic aortic atheromas.
Operative approaches to patients with severe atheroscle-
rosis of the aortic arch and ascending aorta. Aortic arch
endarterectomy as a primary procedure for patients with
previous emboli has been described in three case reports of
relatively young patients (average age 55 years) who had
recurrent emboli despite anticoagulation (15,30,82). There
have been additional case reports of successful arch endar-
terectomy, and this operation was proposed as a possible
standard by which to treat the problem (83). However, it is
clear from the larger series of patients described earlier (69)
that arch endarterectomy greatly increases the risk of major
intraoperative stroke, and this procedure should not be done
on a routine basis.
In a study of 500 patients having cardiac surgery, the
aorta was evaluated with intraoperative epiaortic ultrasound
(68). In the 68 patients with ascending aortic atherosclero-
sis, various changes in technique were used in an attempt to
prevent stroke (changing the site of cannulation, clamping
or graft anastomosis and graft replacement [n 5 10] of the
ascending aorta). There was only one neurologic event in
these 68 patients (1.5%). This series was expanded in a
subsequent report of 231 patients with moderate or severe
ascending aortic atherosclerosis (84). Replacement of the
ascending aorta in 27 patients resulted in an intraoperative
stroke rate of 0%.
In 111 other patients with ascending atherosclerosis,
interventions short of replacement of the ascending aorta
were undertaken in an attempt to avoid manipulating,
cannulating or clamping the diseased segments. These
maneuvers included use of the femoral artery or alternate
sites in the ascending aorta or arch for cannulation; no aortic
clamping or placement of the clamp more proximally in the
ascending aorta or arch; retrograde (coronary sinus) cardio-
plegia installation or the use of hypothermic fibrillatory
arrest; and alternate sites on the ascending aorta for attach-
ment of the proximal coronary grafts. The stroke rate in
these 111 patients with more minor interventions was nearly
fourfold higher than the general stroke rate in 1,200
consecutive patients (6.3% vs. 1.6%).
To summarize the current data regarding operative inter-
ventions during cardiac surgery requiring cardiopulmonary
bypass in patients with significant atheromas of the aortic
arch and ascending aorta, 1) arch endarterectomy is gener-
ally counterproductive and its use should be restricted to
good (relatively young) operative candidates with recurrent
critical events despite other therapy; 2) attempts to avoid
manipulation and cannulation of diseased segments appear
to be prudent, but do not necessarily prevent stroke; and 3)
graft replacement of the ascending aorta is feasible and
resulted in no intraoperative strokes in 27 reported cases.
Replacement of the ascending aorta does not address
significant disease more distally (in the arch), and its
successful outcome depends on a surgical group with the
skill and experience to accomplish this with excellent results
similar to those in the published studies. Finally, the
presence of ascending or aortic arch atheromas on trans-
esophageal echocardiography or intraoperative epiaortic ul-
trasound is a contraindication to the use of the new,
minimally invasive port-access techniques for heart surgery,
as the intra-aortic endoclamp used with these techniques
cannot be advanced safely into the ascending aorta in such
patients (85).
Minimally invasive direct coronary artery bypass graft
surgery (MIDCAB) is a procedure that allows stabilization
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of coronary artery segments so that they can be grafted while
the heart is beating. Most often, the left internal mammary
artery is grafted to the left anterior descending coronary
artery as the primary procedure (with no need for a proximal
aortic anastomosis). Because no cardiopulmonary bypass is
used, stroke and peripheral embolization due to manipula-
tion of the thoracic aorta may be avoided in patients with
aortic atheromas. Early reports of this technique in patients
with aortic arch atheromas on transesophageal echocardi-
ography have shown that the procedure can be performed
without intraoperative stroke (86,87), although MIDCAB
did not prevent neuropsychiatric dysfunction in one small
study (88). Further data will help to evaluate the utility of
the MIDCAB technique for patients with atheromas who
require CABG. The technique obviously does not apply to
those requiring valve operations.
Cardiac catheterization. The studies cited earlier docu-
ment an association between aortic plaque and embolic
complications due to the passage of catheters, and debris can
be retrieved from coronary guiding catheters in many
patients with such plaque (59,62). There are no trials of
various maneuvers to prevent embolic complications due to
catheterization of the aorta; however, a right brachial
approach (rather than femoral), by definition, avoids athe-
romas in the femoral and iliac arteries, the abdominal and
descending aorta and the aortic arch. Ascending aortic
atheromas are less common than arch atheromas, and the
plaque burden increases further in the descending aorta
(53). Innominate atheromas are not visible on transesoph-
ageal echocardiography, but they are uncommon (only five
were seen in 520 MRI studies of the great vessels in one
series (unpublished data). Such an approach must still
traverse the innominate artery and ascending aorta, but it is
possible that this may entail less risk than that with
traditional femoral catheterization, and this brachial ap-
proach has been proposed for patients with peripheral
vascular disease (89).
Conclusions. Aortic atheromas have been recognized,
along with carotid artery disease and atrial fibrillation, as a
leading cause of embolic stroke and peripheral organ dam-
age. The prevalence of thoracic aortic atheromas (;27% in
patients with previous events) is on the same order of
magnitude as the other two etiologies, and atheromas are
therefore responsible for many so-called “cryptogenic
strokes.” Plaque thickness and superimposed mobile
thrombi are risk factors for embolic events, and plaque
ulceration and the absence of calcification (lipid-rich
plaques?) may be as well. When atheromas were present, the
incidence of future stroke in three separate studies was 12%
in a single year, and the incidence of stroke or peripheral
embolic events was as high as 33%. The technique of choice
for the diagnosis of this condition is transesophageal echo-
cardiography, which is only minimally invasive and can be
performed at the bedside in awake patients. Transesopha-
geal echocardiography has also been shown to be cost-
effective in stroke patients (90).
The vital question of therapy remains to be answered.
Although aortic arch endarterectomy is technically possible,
its routine use as an adjunct to cardiac surgery in patients
with arch atheromas should be abandoned, as the procedure
greatly increases the stroke risk. Anticoagulant agents have
been associated with fewer strokes in the published data;
however, their role, as well as that of antithrombotic drugs
and strategies to promote atheroma stabilization and regres-
sion, must be evaluated in prospective, randomized clinical
trials that are sufficiently sized to detect a significant
treatment effect or detriment.
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